Your browser doesn't support javascript.
loading
Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320).
Otani, Sakiko; Sasaki, Jiichiro; Nakahara, Yoshiro; Fukui, Tomoya; Igawa, Satoshi; Naoki, Katsuhiko; Bessho, Akihiro; Hosokawa, Shinobu; Fukamatsu, Nobuaki; Nakamura, Yukiko; Kasai, Takashi; Sugiyama, Tomohide; Tokito, Takaaki; Seki, Nobuhiko; Hamada, Akinobu; Okamoto, Hiroaki; Masuda, Noriyuki.
Afiliação
  • Otani S; Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara city, Kanagawa, 252-0375, Japan. sakiko.o@kitasato-u.ac.jp.
  • Sasaki J; Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara city, Kanagawa, 252-0375, Japan.
  • Nakahara Y; Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara city, Kanagawa, 252-0375, Japan.
  • Fukui T; Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara city, Kanagawa, 252-0375, Japan.
  • Igawa S; Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara city, Kanagawa, 252-0375, Japan.
  • Naoki K; Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara city, Kanagawa, 252-0375, Japan.
  • Bessho A; Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, 2-1-1, aoe,Kita-ku, Okayama-city, 700-8607, Japan.
  • Hosokawa S; Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, 2-1-1, aoe,Kita-ku, Okayama-city, 700-8607, Japan.
  • Fukamatsu N; Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, 2-1-1, aoe,Kita-ku, Okayama-city, 700-8607, Japan.
  • Nakamura Y; Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, 56, Okazawa-cho, Hodogaya-ku, Yokohama city, Kanagawa, 240-8555, Japan.
  • Kasai T; Division of Thoracic Oncology, Tochigi Cancer Center, 4-9-13, Yonan, Utsunomiya-city, Tochigi, 320-0834, Japan.
  • Sugiyama T; Division of Thoracic Oncology, Tochigi Cancer Center, 4-9-13, Yonan, Utsunomiya-city, Tochigi, 320-0834, Japan.
  • Tokito T; Division of Respirology, Neurology, and Rheumatology, Department ofInternal Medicine, Kurume University School of Medicine, 67, Asahimachi, Kurume-city, Fukuoka, 830-0011, Japan.
  • Seki N; Division of Medical oncology, Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-0014, Japan.
  • Hamada A; Division of Molecular Pharmacology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Okamoto H; Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, 56, Okazawa-cho, Hodogaya-ku, Yokohama city, Kanagawa, 240-8555, Japan.
  • Masuda N; Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara city, Kanagawa, 252-0375, Japan.
Invest New Drugs ; 39(2): 530-536, 2021 04.
Article em En | MEDLINE | ID: mdl-33159674
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Antraciclinas / Cloridrato de Erlotinib / Neoplasias Pulmonares / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Antraciclinas / Cloridrato de Erlotinib / Neoplasias Pulmonares / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão